SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950142-22-002339
Filing Date
2022-07-28
Accepted
2022-07-28 17:02:39
Documents
13
Period of Report
2022-07-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh220274812_8k.htm   iXBRL 8-K 26010
  Complete submission text file 0000950142-22-002339.txt   243221

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nrxp-20220722.xsd EX-101.SCH 3690
3 XBRL DEFINITION FILE nrxp-20220722_def.xml EX-101.DEF 26608
4 XBRL LABEL FILE nrxp-20220722_lab.xml EX-101.LAB 36687
5 XBRL PRESENTATION FILE nrxp-20220722_pre.xml EX-101.PRE 25232
7 EXTRACTED XBRL INSTANCE DOCUMENT eh220274812_8k_htm.xml XML 5562
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 221116057
SIC: 2834 Pharmaceutical Preparations